Amgen Inc.

Blinkbio, Inc.

Hanh Nho Nguyen

Karina Romero

Holly L Deak

Isaac E Marx

Matthew M Weiss

Brian Lewis Hodous

Thomas Dineen

Erin F DiMauro

Victor J Cee

Douglas S Werner

Stephanie Geuns-Meyer

Leslie Odame Ofori

Jutta Wanner

Vinod Francis Patel

Charles Kreiman

Philip R Olivieri

Emily Anne Peterson

Daniel La

Russell Graceffa

Alessandro Boezio

Bingfan Du

Christiane Boezio

Ryan D White

Yuan Cheng

Angel Guzman-Perez

Laurie B Schenkel

Nagasree Chakka

Howard Bregman

Hongbing Huang

Ning Xi

Joseph L Kim

Brian K Albrecht

Xiaotian Zhu

Steven F Bellon

Paul A Tempest

Stuart C Chaffee

Jason Brooks Human

Zihao Hua

Xiao Mei Zheng

Kenneth W Foreman

John R Butler

Katrina Woodin Copeland

Margaret Chu-Moyer

Brian Andrew Sparling

James R Coats

Rebecca E Johnson

Matthew W Martin

Patricia Lopez

Qingyian Liu

Qiufen May Xue

Wenge Zhong

Ana Elena Minatti

Albert Kudzovi Amegadzie

Ted Charles Judd

Vu Van Ma

Alan C Cheng

James A Brown

Wenyuan Qian

Nick A Paras

Vijay Keshav Gore

John Laird Buchanan

Oleg Epstein

Benjamin Charles Milgram

Kathleen Panter

Hua Gao

Karina R Vaida

Kate Panter

Mathew Martin

Phillip R Olivieri

Benjamin Charles Milgrim

Stephanie D Geuns-meyer

Stephanie D Geuns-Meyer

Laurie Schenkel

Vinod F Patel

Stephanie D Guens-Meyer

Brian L Houdous

Philipp R Olivieri

Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.

Silanol based therapeutic payloads

Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

Silicon based drug conjugates and methods of using same

The present invention provides compounds of Formula I or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Bicyclic sulfonamide compounds as sodium channel inhibitors

The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors

The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Carboxamides as inhibitors of voltage-gated sodium channels

The present invention relates to chemical compounds having a general formula I wherein A, L, R, Rand n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds and methods of treating disease states related to the activity of Aurora kinase.

Aurora kinase modulators and methods of use

The present invention provides compounds of Formula I or II, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Heteroaryl sodium channel inhibitors

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.  The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

Bicyclic aryl and heteroaryl sodium channel inhibitors

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A, A, A, A, A, A, R, R, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use

Growing community of inventors

Arlington, MA, United States of America

Hanh Nho Nguyen